Table 1.
Patient characteristics.
| Variable | n/30 (%) |
|---|---|
| Age in years—mean (range) | 55.6 (29–85) |
| Gender | Female 15 (50%) |
| Male 15 (50%) | |
| Underlying or related diseases | Lymphoma 2 (6.7%) |
| Leukemia 1 (3.3%) | |
| Solid cancer 7 (23.2%) | |
| Basocellular carcinoma 2 (6.7%) | |
| Breast carcinoma 2 (6.7%) | |
| Lung adenocarcinoma 1 (3.3%) | |
| Seminoma 1 (3.3%) | |
| Thymoma 1 (3.3%) | |
| Chronic liver disease 1 (3.3%) | |
| Chronic kidney disease 1 (3.3%) | |
| Nephrotic syndrome 1 (3.3%) | |
| Autoimmune diseases (33.3%) | |
| Thrombotic thrombocytopenic purpura 2 (6.7%) | |
| Celiac disease 1 (3.3%) | |
| Collagenous colitis 1 (3.3%) | |
| Crohn’s disease 1 (3.3%) | |
| Ulcerative proctitis 1 (3.3%) | |
| Autoimmune anemia 1 (3.3%) | |
| Lupus-like syndrome 1 (3.3%) | |
| Membranoproliferative glomerulonephritis type 1 1 (3.3%) | |
| PR3-ANCA-associated vasculitis 1 (3.3%) | |
| GLILD 3 (10%) | |
| Asthma 6 (20%) | |
| Drug or food allergies 9 (30%) | |
| Immunosuppressive agents used in the last 3 months | Azathioprine 2 (6.7%) |
| Mycophenolate 1 (3.3%) | |
| Corticosteroids 1 (3.3%) | |
| Rituximab + corticosteroids 1 (3.3%) | |
| Previous rituximab | 6 (20%) |
| ESID registry for Immunodeficiency [12] | Combined Immunodeficiency 1 (3.3%) |
| Common Variable Disorders 14 (46.7%) | |
| Secondary Immunodeficiency 3 (10%) | |
| Thymoma with Immunodeficiency 1 (3.3%) | |
| Unclassified Antibody Deficiency 11 (36.7%) | |
| Years since diagnose diagnosis—mean (range) | 7.87 (0–31) |
| Type of Immunoglobulin deficiency in PID/SID | IgG 6 (20%) |
| IgG + IgA 4 (13.3%) | |
| IgG + IgA + IgM 16 (53.3%) | |
| IgG + IgM 4 (13.3%) | |
| IgG subclass deficiency | IgG 1 4 (13.3%) |
| IgG 1 + 2 + 3 1 (3.3%) | |
| IgG 1 + 2 + 3 + 4 6 (20%) | |
| IgG 1 + 2 + 4 13 (43.3%) | |
| No subclass affected 6 (20%) | |
| Isohemagglutinin evaluation | Total evaluated 23 (76.7%) |
| High rates 8 (26.7%) | |
| Low rates 13 (43.3%) | |
| Not evaluable 1 2 (6.7%) | |
| Polysaccharide Typhim Vi® Antibody Response | Total evaluated 13/30 (43.3%) |
| Adequate 6 (20%) | |
| Non-adequate 7 (23.3%) | |
| Type of Immunoglobulin Replacement Therapy (IRT) | Subcutaneous 17 (56.6%) |
| Intravenous 13 (43.4%) | |
| Years in IRT | <1 year 5 (16.6%) |
| 1–5 years 13 (43.3%) | |
| 5–10 years 6 (20%) | |
| >10 years 6 (20%) | |
| Last available IgG trough levels—mean (range) | 797 mg/dL (233–1112) |
| Previous COVID-19 infection | 4 (13.3%) |
| WHO-SCORE in COVID-19 infection [13] | Score 1 1 (3.3%) |
| Score 2 1 (3.3%) | |
| Score 5 2 (6.7%) | |
| IgG SARS-CoV-2 (June/2020) | Positive 1 (3.3%) |
| Negative 28 (93.3%) |
1 Not applicable in the case of AB blood group.